Celcuity (NASDAQ:CELC) Trading 8.1% Higher on Analyst Upgrade

Celcuity, Inc. (NASDAQ:CELC)’s stock price traded up 8.1% during mid-day trading on Friday after Craig Hallum raised their price target on the stock from $96.00 to $108.00. Craig Hallum currently has a buy rating on the stock. Celcuity traded as high as $93.04 and last traded at $92.9760. 696,304 shares changed hands during mid-day trading, a decline of 4% from the average session volume of 727,632 shares. The stock had previously closed at $86.00.

Other equities research analysts also recently issued research reports about the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Celcuity in a research note on Wednesday, October 8th. Stifel Nicolaus upped their price objective on shares of Celcuity from $68.00 to $115.00 and gave the stock a “buy” rating in a research note on Thursday. Needham & Company LLC set a $95.00 price objective on shares of Celcuity in a report on Monday, October 20th. Guggenheim began coverage on Celcuity in a research note on Monday, September 22nd. They issued a “buy” rating on the stock. Finally, Leerink Partners raised their target price on Celcuity from $28.00 to $60.00 and gave the company an “outperform” rating in a research note on Monday, July 28th. Six equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Celcuity presently has a consensus rating of “Moderate Buy” and a consensus price target of $91.00.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Baker BROS. Advisors LP raised its holdings in Celcuity by 59.0% during the 1st quarter. Baker BROS. Advisors LP now owns 4,257,735 shares of the company’s stock worth $43,046,000 after buying an additional 1,579,182 shares during the period. Soleus Capital Management L.P. raised its holdings in shares of Celcuity by 17.0% during the second quarter. Soleus Capital Management L.P. now owns 3,011,818 shares of the company’s stock worth $40,208,000 after acquiring an additional 437,696 shares during the period. Vanguard Group Inc. raised its holdings in shares of Celcuity by 23.5% during the third quarter. Vanguard Group Inc. now owns 2,059,047 shares of the company’s stock worth $101,717,000 after acquiring an additional 391,262 shares during the period. Eventide Asset Management LLC lifted its position in Celcuity by 9.8% in the 2nd quarter. Eventide Asset Management LLC now owns 1,389,427 shares of the company’s stock valued at $18,549,000 after acquiring an additional 123,774 shares in the last quarter. Finally, Saturn V Capital Management LP boosted its stake in Celcuity by 8.4% in the 2nd quarter. Saturn V Capital Management LP now owns 1,185,520 shares of the company’s stock worth $15,827,000 after purchasing an additional 91,843 shares during the period. 63.33% of the stock is currently owned by institutional investors and hedge funds.

Celcuity Stock Performance

The stock has a fifty day simple moving average of $60.87 and a 200-day simple moving average of $36.20. The stock has a market cap of $3.97 billion, a P/E ratio of -25.63 and a beta of 0.72. The company has a debt-to-equity ratio of 2.24, a quick ratio of 4.58 and a current ratio of 4.58.

Celcuity (NASDAQ:CELC) last posted its quarterly earnings data on Wednesday, November 12th. The company reported ($0.92) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.05) by $0.13. The firm had revenue of $0.15 million for the quarter. On average, equities analysts expect that Celcuity, Inc. will post -2.62 earnings per share for the current year.

Celcuity Company Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.